ZERIA PHARMACEUTICAL CO.,LTD. (4559.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	86.6B	89.2B	87.3B	75.7B	68.4B
Cost of Revenue	5.6B	24.0B	23.4B	20.2B	18.9B
Gross Profit	13.9B	65.2B	64.0B	55.5B	49.5B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	12.4B	52.8B	51.8B	45.9B	40.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	12.4B	52.8B	51.8B	45.9B	40.5B
Cost and Expenses	76.1B	76.8B	75.1B	66.1B	59.4B
Operating Income (EBIT)	10.5B	12.4B	12.2B	9.6B	9.0B
Non-Operating
Interest Income	28.5M	111.8M	282.9M	150.9M	67.9M
Interest Expense	121.9M	501.8M	452.3M	457.8M	337.3M
Net Interest Income	(93.3M)	(390.0M)	(169.4M)	(306.9M)	(269.4M)
Other Non-Op Income/Expense	141.9M	(1.3B)	643.3M	(1.1B)	(1.4B)
Non-Operating Income (excl Interest)	322.7M	668.4M	1.2B	501.9M	311.6M
EBT (Pre-Tax Income)	1.7B	11.2B	12.6B	9.5B	7.3B
Income Tax Expense	624.6M	2.8B	2.7B	1.8B	1.1B
Bottom Line
Net Income	7.3B	8.5B	9.9B	7.7B	6.2B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	7.3B	8.5B	9.9B	7.7B	6.2B
Per Share
Basic EPS	¥165	¥192	¥225	¥175	¥140
Diluted EPS	¥165	¥192	—	—	—
Revenue Per Share	¥1,965	¥2,023	¥1,981	¥1,718	¥1,548
Shares
Basic Shares Outstanding	44.1M	44.1M	44.1M	44.1M	44.2M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	19.0B	19.0B	16.0B	14.4B
D&A	—	6.6B	6.8B	6.3B	5.4B
EBIT	10.5B	12.4B	12.2B	9.6B	9.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026